PRNewsWire
15 Jun 2026, 06:34 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Immutep Limited allegedly concealed the failure of its TACTI-004 trial of eftilagimod alfa to meet primary efficacy endpoints. — Failure of a primary efficacy endpoint for a lead drug candidate is a critical negative catalyst for a biotech company's valuation.
-0.80The Schall Law Firm has filed a securities fraud class action lawsuit against Immutep regarding false and misleading statements about trial progress. — Legal action for securities fraud creates additional financial liability and reputational risk, though it follows the primary negative trial news.
-0.40Which stocks this story touches
The company is the subject of a securities fraud class action lawsuit.
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is facing a securities fraud class action lawsuit alleging false and misleading statements regarding clinical trial results.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
4h ago
